PBPIA
PCVX icon

Pivotal bioVenture Partners Investment Advisor’s Vaxcyte PCVX Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.9M Buy
1,425,470
+53,045
+4% +$2.88M 26.92% 1
2026
Q1 		$79.8M Hold
1,372,425
– – 28.51% 1
2025
Q4 		$63.3M Hold
1,372,425
– – 24.48% 1
2025
Q3 		$49.4M Buy
1,372,425
+67,300
+5% +$2.23M 28.58% 1
2025
Q2 		$42.4M Buy
1,305,125
+594,391
+84% +$19.5M 26.3% 2
2025
Q1 		$26.8M Buy
710,734
+6,900
+1% +$552K 21.72% 3
2024
Q4 		$57.6M Buy
703,834
+64,295
+10% +$6.38M 38.91% 1
2024
Q3 		$73.1M Sell
639,539
-153,497
-19% -$13.8M 43.38% 1
2024
Q2 		$59.9M Hold
793,036
– – 46.04% 1
2024
Q1 		$54.2M Hold
793,036
– – 34.82% 1
2023
Q4 		$49.8M Hold
793,036
– – 12.63% 2
2023
Q3 		$40.4M Hold
793,036
– – 16.13% 2
2023
Q2 		$39.6M Buy
793,036
+99,997
+14% +$4.74M 13.06% 2
2023
Q1 		$26M Hold
693,039
– – 10.7% 2
2022
Q4 		$33.2M Sell
693,039
-83,000
-11% -$3.26M 14.45% 2
2022
Q3 		$18.6M Sell
776,039
-56,127
-7% -$1.42M 6.81% 3
2022
Q2 		$18.1M Sell
832,166
-279,319
-25% -$6.46M 9.12% 2
2022
Q1 		$26.8M Hold
1,111,485
– – 12.7% 2
2021
Q4 		$26.4M Sell
1,111,485
-293,936
-21% -$6.84M 11.06% 2
2021
Q3 		$35.7M Hold
1,405,421
– – 12.6% 3
2021
Q2 		$31.6M Hold
1,405,421
– – 12.47% 2
2021
Q1 		$27.8M Sell
1,405,421
-817,549
-37% -$20.6M 8.91% 4
2020
Q4 		$59.1M Buy
+2,222,970
New +$82.6M 19.47% 2

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's PCVX Position: Q2 2026 in Review

Pivotal bioVenture Partners Investment Advisor increased its Vaxcyte (PCVX) stake by 3.9% in Q2 2026, buying an estimated $2.88M and bringing the position to 1,425,470 shares worth $82.9M. The position accounts for 26.92% of the portfolio, ranked #1.

Pivotal bioVenture Partners Investment Advisor first reported a position in PCVX in Q4 2020 and has held it in 23 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Pivotal bioVenture Partners Investment Advisor held 1,425,470 shares of Vaxcyte worth $82.9M as of Q2 2026.
  • Pivotal bioVenture Partners Investment Advisor bought 53,045 Vaxcyte shares in Q2 2026, an estimated $2.88M.
  • Vaxcyte made up 26.92% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q2 2026, its #1 holding.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Vaxcyte in Q4 2020 and has held it in 23 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2026, filed 13 Aug 2026.